Oppenheimer initiates Kala with Outperform, sees attractive growth story. As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Kala Pharmaceuticals with an Outperform rating and $11 price target. With strong initial uptake of Inveltys, and KPI-121 regulatory catalyst in Q3, the analyst believes Kala Pharmaceuticals is well positioned for top line growth. His channel checks with ocular surgeons support Inveltys prescription growth over the next twelve months. Separately, he believes KPI-121 may address a significant unmet need in the nascent dry eye disease market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.